Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series

BACKGROUND: Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be an effective treatment for NRG1 fusion‐driven tumors. PATIENTS AND METHODS: This report summarizes pertinent details, includ...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Cadranel, Jacques, Liu, Stephen V., Duruisseaux, Michaël, Branden, Eva, Goto, Yasushi, Weinberg, Benjamin A., Heining, Christoph, Schlenk, Richard F., Cheema, Parneet, Jones, Martin R., Drilon, Alexander, Trombetta, Domenico, Muscarella, Lucia Anna, Tolba, Khaled, Gounant, Valerie, Cseh, Agnieszka, Solca, Flavio, Laskin, Janessa J., Renouf, Daniel J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Precision Medicine Clinic: Molecular Tumor Board
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794194/
https://ncbi.nlm.nih.gov/pubmed/32852072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0379
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi